key: cord-0043548-7hvdgju3
authors: He, Yueyue
title: Translation: Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7): National Health Commission, National Administration of Traditional Chinese Medicine
date: 2020-04-17
journal: nan
DOI: 10.1097/im9.0000000000000022
sha: 428676585dc3ba2efd6ae254f30e30f45033dbc3
doc_id: 43548
cord_uid: 7hvdgju3

The National Health Commission of the People's Republic of China has released the document: Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia to standardize the diagnosis and treatment of COVID-19

The novel coronaviruses belong to the β genus. They have envelopes, and the particles are round or oval, often polymorphic, with diameter being 60 to 140 nm. Their genetic characteristics are significantly different from SARS-CoV and MERS-CoV. Current research shows that they share more than 85% homology with bat SARS-like coronaviruses (bat-SL-CoVZC45). When isolated and cultured in vitro, the 2019-nCoV can be found in human respiratory epithelial cells in about 96 hours, however it takes about 6 days for the virus to be found if isolated and cultured in Vero E6 and Huh-7 cell lines.

Most of the knowledge about the physical and chemical properties of coronavirus comes from the research on SARS-CoV and MERS-CoV. The virus is sensitive to ultraviolet and heat. Exposure to 56°C for 30 minutes and lipid solvents such as ether, 75% ethanol, chlorine-containing disinfectant, peracetic acid, and chloroform can effectively inactivate the virus. Chlorhexidine has not been effective in inactivating the virus.

Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source.

Transmission of the virus happens mainly through respiratory droplets and close contact. There is the possibility of aerosol transmission in a relatively closed environment for a long-time exposure to high concentrations of aerosol. As the novel coronavirus can be isolated in feces and urine, attention should be paid to feces or urine contaminated environment that may lead to aerosol or contact transmission.

People are generally susceptible.

Pathological findings from limited autopsies and biopsy studies are summarized below:

Variable consolidation is present in the lungs. The alveoli are filled with fluid and fibrin with hyaline membrane formation. Macrophages and many multinucleated syncytial cells are identified within the alveolar exudates. Type II pneumocytes show marked hyperplasia and focal desquamation. Viral inclusions are observed in type II pneumocytes and macrophages. In addition, there is prominent edema and congestion in the alveolar septa which are infiltrated by monocytes and lymphocytes. Fibrin microthrombi are present. In more severely affected area, hemorrhage, necrosis, and overt hemorrhagic infarction are seen. Organization of alveolar exudates and interstitial fibrosis are also present.

Detached epithelial cell and mucus are present in the bronchi, sometimes mucus plugs are seen.

Hyperventilated alveoli, interrupted alveolar interstitium and cystic formation are occasionally seen.

By electronic microscopy, cytoplasmic 2019-nCoV virions are observed in the bronchial epithelium and type II pneumocytes. Immunostain reveals 2019-nCoV viral immunereactivity in some alveolar epithelial cells and macrophages and RT-PCR confirms the presence of 2019-nCoV nucleic acid.

The spleen is markedly atrophic with a decreased number of lymphocytes. Focal hemorrhage and necrosis are present. Macrophages proliferation and phagocytosis are present in the spleen. Sparsity of lymphocytes and focal necrosis are noted in lymph nodes. Immunohistochemistry highlights a decreased number of CD 4+ and CD 8+ T cells in the spleen and lymph nodes. Myelopoiesis is decreased in bone marrow.

Degenerated or necrosed myocardial cells are present, along Infectious Microbes and Diseases, Publish Ahead of Print DOI: 10.1097/IM9.0000000000000022 with mild infiltration of monocytes, lymphocytes and/or neutrophils in the cardiac interstitium. Shedding of endothelial cells, endovasculitis and thrombi are seen in some blood vessels.

The liver is dark-red and enlarged. Degeneration and focal necrosis of hepatocytes are found, accompanied by infiltration of neutrophils. The sinusoids are congested. The portal areas are infiltrated by lymphocytes and histiocytes. Microthrombi are seen. The gallbladder is prominently distended.

The kidneys are remarkable for proteinaceous exudates in the Bowman's capsule around glomeruli, degeneration and shedding of renal tubules epithelial cells, and hyaline casts. Microthrombi and fibrotic foci are found in the kidney interstitium.

Cerebral hyperemia and edema are present, with degeneration of some neurons. Necrotic foci are noted in the adrenal glands. Degeneration, necrosis and desquamation of epithelium mucosae of variable degree are present in the esophageal, stomach and bowel.

Based on the current epidemiological investigation, the incubation period is one to 14 days, mostly three to seven days.

The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases. Severe patients develop dyspnea and/or hypoxemia after one week and may progress rapidly to acute respiratory distress syndrome, septic shock, refractory metabolic acidosis, coagulopathy, multiple organ failure etc. It is noteworthy that for severe and critically ill patients may only present with moderate to low fever, or even no fever at all. Some children and neonatal patients may have atypical symptoms, presented with gastrointestinal symptoms such as vomiting and diarrhea, or only manifested as lethargy and shortness of breath.

The patients with mild symptoms usually do not develop pneumonia but have low fever and mild fatigue.

Based on our experience, most patients have good prognosis and a small percentage of patients are critically ill. The prognosis for the elderly and patients with chronic underlying diseases is poorer. The clinical course of pregnant women with COVID-19 is similar to that of non-pregnant patients of the same age. Symptoms in children are relatively mild.

In the early stages of the disease, peripheral white blood cell (WBC) count is normal or decreased and the lymphocyte count is decreased. Some patients have elevated liver enzymes, lactate dehydrogenase (LDH), muscle enzymes and myoglobin. Elevated troponin is seen in some critically ill patients. Most patients have elevated C-reactive protein (CRP) and erythrocyte sedimentation rate and normal procalcitonin. In severe cases, D-dimer increases and peripheral blood lymphocytes progressively decrease. Severe and critically ill patients often have elevated inflammatory factors.

Pathogenic and serological findings

(1) Pathogenic findings: Novel coronavirus nucleic acid can be detected in nasopharyngeal swabs, sputum, lower respiratory tract secretions, blood, feces and other specimens using RT-PCR and/or NGS methods. It is more accurate if specimens are obtained from lower respiratory tract (sputum or air tract extraction). The specimens should be submitted for testing as soon as possible after collection. (2) Serological findings: COVID-19 virus specific IgM becomes detectable around 3-5 days after onset; IgG reaches a titration of at least 4-fold increase during convalescence compared with the acute phase.

In the early stage, imaging shows multiple small patchy shadows and interstitial changes, more apparent in the peripheral zone of lungs. As the disease progresses, imaging shows multiple ground glass opacities and infiltration in both lungs. In severe cases, pulmonary consolidation may occur. However, pleural effusion is rare.

Considering both the following epidemiological history and clinical manifestations:

1. A suspect case has any of the epidemiological history plus any two clinical manifestations or all three clinical manifestations if there is no clear epidemiological history.

Suspect cases with one of the following etiological or serological evidences: 2.1 Real-time fluorescent RT-PCR indicates positive for new coronavirus nucleic acid; 2.2 Viral gene sequence is highly homologous to known new coronaviruses.

2.3 COVID-19 virus specific IgM and IgG are detectable in serum; COVID-19 virus specific IgG is detectable or reaches a titration of at least 4-fold increase during convalescence compared with the acute phase.

The clinical symptoms were mild, and there was no sign of pneumonia on imaging.

Showing fever and respiratory symptoms with radiological findings of pneumonia.

Adult cases meeting any of the following criteria:

(1) Respiratory distress (≥ 30 breaths/min);

(2) Oxygen saturation ≤ 93% at rest;

(3) Arterial partial pressure of oxygen (PaO 2 )/raction of inspired oxygen (FiO 2 ) ≤ 300mmHg (lmmHg = 0.133kPa). In high-altitude areas (at an altitude of over 1,000 meters above the sea level), PaO 2 /FiO 2 shall be corrected by the following formula:

Cases with chest imaging that shows obvious lesion progression within 24-48 hours > 50% shall be managed as severe cases.

Child cases meeting any of the following criteria:

(1) Tachypnea (RR ≥ 60 breaths/min for infants aged below 2 months; RR ≥ 50 breaths/min for infants aged 2-12 months; RR ≥ 40 breaths/min for children aged 1-5 years, and RR ≥ 30 breaths/min for children above 5 years old) independent of fever and crying; (2) Oxygen saturation ≤ 92% on finger pulse oximeter taken at rest; (3) Labored breathing (moaning, nasal fluttering, and infrasternal, supraclavicular and intercostal retraction), cyanosis, and intermittent apnea; (4) Lethargy and convulsion; (5) Difficulty feeding and signs of dehydration.

Cases meeting any of the following criteria: 4.1 Respiratory failure and requiring mechanical ventilation; 4.2 Shock; 4.3 With other organ failure that requires ICU care. 2.5 Infants under the age of 3 months who have either underlying diseases (congenital heart disease, bronchopulmonary dysplasia, respiratory tract deformity, abnormal hemoglobin, and severe malnutrition, etc.) or immune deficiency or hypofunction (long-term use of immunosuppressants).

1. The mild manifestations of COVID-19 need to be distinguished from those of upper respiratory tract infections caused by other viruses.

2. COVID-19 is mainly distinguished from other known viral pneumonia and mycoplasma pneumoniae infections such as influenza virus, adenovirus and respiratory syncytial virus. For suspect cases, efforts should be made to use methods such as rapid antigen detection and multiplex PCR nucleic acid testing for detection of common respiratory pathogens.

3. COVID-19 should also be distinguished from noninfectious diseases such as vasculitis, dermatomyositis and organizing pneumonia.

Health professionals in medical institutions of all types and at all levels, upon discovering suspect cases that meet the definition, should immediately keep them in single room for isolation and treatment. If the cases are still considered as suspected after consultation made by hospital experts or attending physicians, it should be reported directly online within 2 hours; samples should be collected for new coronavirus nucleic acid testing and suspect cases should be safely transferred to the designated hospitals immediately. People who have been in close contact with confirmed patients are advised to perform new coronavirus pathogenic testing in a timely manner, even though common respiratory pathogens are tested positive.

If two nucleic acid tests, taken at least 24-hour apart, of a COVID-19 suspect case are negative, and the COVID-19 virus specific IgM and IgG are negative after 7 days from onset, the suspect diagnosis can be ruled out.

1.1 Suspected and confirmed cases should be isolated and treated at designated hospitals with effective isolation, protection and prevention conditions in place. A suspect case should be treated in isolation in a single room. Confirmed cases can be treated in the same room.

1.2 Critical cases should be admitted to ICU as soon as possible.

2.1 Letting patients rest in bed and strengthening support therapy; ensuring sufficient caloric intake for patients; monitoring their water and electrolyte balance to maintain internal environment stability; closely monitoring vital signs and oxygen saturation.

2.2 According to patients' conditions, monitoring blood routine result, urine routine result, CRP, biochemical indicators (liver enzyme, myocardial enzyme, renal function etc.), coagulation function, arterial blood gas analysis, chest imaging and cytokines detection if necessary.

2.3 Timely providing effective oxygen therapy, including nasal catheter and mask oxygenation and nasal high-flow oxygen therapy. If possible, inhalation of mixed hydrogen and oxygen (H 2 /O 2 : 66.6%/33.3%) can be applied.

2.4 Antiviral therapy: Hospitals can try Alpha-interferon (5 million unit or equivalent dose each time for adults, adding 2ml of sterilized water, atomization inhalation twice daily), lopinavir/ritonavir (200mg/50mg per pill for adults, two pills each time, twice daily, no longer than 10 days), Ribavirin (suggested to be used jointly with interferon or lopinavir/ ritonavir, 500mg each time for adults, twice or three times of intravenous injection daily, no longer than 10 days), chloroquine phosphate (500mg bid for 7 days for adults aged 18-65 with body weight over 50kg; 500mg bid for Days 1&2 and 500mg qd for Days 3-7 for adults with body weight below 50kg), Arbidol (200mg tid for adults, no longer than 10 days). Be aware of the adverse reactions, contraindications (for example, chloroquine cannot be used for patients with heart diseases) and interactions of the above-mentioned drugs. Further evaluate the efficacy of those drugs currently being used. Using three or more antiviral drugs at the same time is not recommend; if an intolerable toxic side effect occurs, the respective drug should be discontinued. For the treatment of pregnant women, issues such as the number of gestational weeks, choice of drugs having the least impact on the fetus, as well as whether pregnancy being terminated before treatment should be considered with patients being informed of these considerations.

2.5 Antibiotic drug treatment: Blind or inappropriate use of antibiotic drugs should be avoided, especially in combination with broad-spectrum antibiotics.

3.1 Treatment principle: On the basis of symptomatic treatment, complications should be proactively prevented, underlying diseases should be treated, secondary infections also be prevented, and organ function support should be provided timely.

3.2 Respiratory support: 3.2.1 Oxygen therapy: Patients with severe symptoms should receive nasal cannulas or masks for oxygen inhalation and timely assessment of respiratory distress and/or hypoxemia should be performed.

3.2.2 High-flow nasal-catheter oxygenation or noninvasive mechanical ventilation: When respiratory distress and/or hypoxemia of the patient cannot be alleviated after receiving standard oxygen therapy, high-flow nasal cannula oxygen therapy or non-invasive ventilation can be considered. If conditions do not improve or even get worse within a short time (1-2 hours), tracheal intubation and invasive mechanical ventilation should be used in a timely manner.

3.2.3 Invasive mechanical ventilation: Lung protective ventilation strategy, namely low tidal volume (6-8ml/kg of ideal body weight) and low level of airway platform pressure (<30cmH 2 O) should be used to perform mechanical ventilation to reduce ventilator-related lung injury. While the airway platform pressure maintained ≤ 30cmH 2 O, high PEEP can be used to keep the airway warm and moist; avoid long sedation and wake the patient early for lung rehabilitation. There are many cases of human-machine asynchronization, therefore sedation and muscle relaxants should be used in a timely manner. Use closed sputum suction according to the airway secretion, if necessary, administer appropriate treatment based on bronchoscopy findings.

3.2.4 Rescue therapy: Pulmonary re-tensioning is recommended for patients with severe ARDS. With sufficient human resources, prone position ventilation should be performed for more than 12 hours per day. If the outcome of prone position ventilation is poor, extracorporeal membrane oxygenation (ECMO) should be considered as soon as possible. Indications include: ①When FiO 2 ＞ 90%, the oxygenation index is less than 80mmHg for more than 3-4 hours; ②For patients with only respiratory failure when the airway platform pressure ≥ 35cmH 2 O, VV-ECMO mode is preferred; if circulatory support is needed, VA-ECMO mode should be used.

When underlying diseases are under control and the cardiopulmonary function shows signs of recovery, withdrawal of ECMO can be tried.

3.3 Circulatory support: On the basis of adequate fluid resuscitation, efforts should be made to improve microcirculation, use vasoactive drugs, closely monitor changes in blood pressure, heart rate and urine volume as well as lactate and base excess in arterial blood gas analysis. If necessary, use non-invasive or invasive hemodynamic monitor such as Doppler ultrasound, echocardiography, invasive blood pressure or continuous cardiac output (PiCCO) monitoring. In the process of treatment, pay attention to the liquid balance strategy to avoid excessive or insufficient fluid intake.

If the heart rate suddenly increases more than 20% of the basic value or the decrease of blood pressure is more than 20% of the basic value with manifestations of poor skin perfusion and decreased urine volume, make sure to closely observe whether the patient has septic shock, gastrointestinal hemorrhage or heart failure.

3.4 Renal failure and renal replacement therapy: Active efforts should be made to look for causes for renal function damage in critical cases such as low perfusion and drugs. For the treatment of patients with renal failure, focus should be on the balance of body fluid, acid and base and electrolyte balance, as well as on nutrition support including nitrogen balance and the supplementation of energies and trace elements. For critical cases, continuous renal replacement therapy (CRRT) can be used. The indications include: ① hyperkalemia; ② acidosis; ③ pulmonary edema or water overload; ④ fluid management in multiple organ dysfunction.

3.5 Convalescent plasma treatment: It is suitable for patients with rapid disease progression, severe and critically ill patients. Usage and dosage should refer to Protocol of Clinical Treatment with Convalescent Plasma for COVID-19 Patients (2nd trial version).

3.6 Blood purification treatment: Blood purification system including plasma exchange, absorption, perfusion and blood/ plasma filtration can remove inflammatory factors and block "cytokine storm", so as to reduce the damage of inflammatory reactions to the body. It can be used for the treatment of severe and critical cases in the early and middle stages of cytokine storm.

3.7 Immunotherapy: For patients with extensive lung lesions and severe cases who also show an increased level of IL-6 in laboratory testing, Tocilizumab can be used for treatment. The initial dose is 4-8mg/kg with the recommended dose of 400mg diluted with 0.9% normal saline to 100ml. The infusion time should be more than 1 hour. If the initial medication is not effective, one extra administration can be given after 12 hours (same dose as before). No more than two administrations should be given with the maximum single dose no more than 800mg. Watch out for allergic reactions. Administration is forbidden for people with active infections such as tuberculosis.

3.8 Other therapeutic measures For patients with progressive deterioration of oxygenation indicators, rapid progress in imaging and excessive activation of the body's inflammatory response, glucocorticoids can be used in a short period of time (three to five days). It is recommended that dose should not exceed the equivalent of methylprednisolone 1-2mg/kg/day. Note that a larger dose of glucocorticoid will delay the removal of coronavirus due to immunosuppressive effects. Xuebijing 100ml/time can be administered intravenously twice a day. Intestinal microecological regulators can be used to maintain intestinal microecological balance and prevent secondary bacterial infections.

Child severe and critical cases can be given intravenous infusion of γ-globulin. For pregnant severe and critical cases, pregnancy should be terminated preferably with c-section.

Patients often suffer from anxiety and fear and they should be supported by psychological counseling.

This disease belongs to plague in traditional Chinese medicine (TCM), caused by the epidemic pathogenic factors. According to the different local climate characteristic and individual state of illness and physical conditions, the following treatment Protocol may vary. The use of over-pharmacopoeia doses should be directed by a physician.

4 Suggested use: TCM decoction pieces for decocting in water. One dose daily with half of the dose taken in the morning and half in the evening (forty minutes after meal) with warm water. Three days make a course of treatment.

If conditions permit, the patient can take half a bowl of rice soup each time after taking the medicine, and can take up to one bowl if the patient has a dry tongue and is deficient in bodily fluids. (Note: If the patient does not have a fever, the amount of gypsum should be little. If having a fever or high fever, the amount of gypsum can be increased). If the symptoms improve but do not fully recover, then take the second course of treatment. If the patient has special conditions or other underlying diseases, the prescription of the second course of treatment can be modified based on the actual situation and the medicine should be discontinued when the symptoms disappear.

Source Clinical manifestations: fever, fatigue, sore body, cough, expectoration, chest tightness, suffocation, loss of appetite, nausea, vomiting, sticky stools. Tongue has thin fat tooth mark or is light red, and the coating is white thick rot or white greasy and the pulse is soggy or slippery.

(3) Pulmonary imaging shows obvious absorption of inflammation; (4) Nucleic acid tests negative twice consecutively on respiratory tract samples such as sputum and nasopharyngeal swabs (sampling interval being at least 24 hours). Those who meet the above criteria can be discharged.

2.1 The designated hospitals should contact the primary healthcare facilities where the patients live and share patients' medical record, to send the information of the discharged patients to the community committee and primary healthcare facility where the patients reside.

2.2. After discharge, it is recommended for patients to monitor their own health status in isolation for 14 days, wear a mask, live in well-ventilated single room if possible, minimize close contact with family members, separate dinning, practice hand hygiene and avoid going out.

2.3 It is recommended for the patients to return to the hospitals for follow-up and re-visit in two and four weeks after discharge.

Patients should be transported in accordance with the Work Protocol for Transfer of the Novel Coronavirus Pneumonia Patients (Trial Version) issued by the National Health Commission.

Measures to prevent and control nosocomial infection should be implemented in accordance with the requirements of the Technical Guidelines for the Prevention and Control of Infection by the Novel Coronavirus in Medical Institutions (First Edition) and the Guidelines on the Usage of Common Medical Protective Equipment against Novel Coronavirus Infection (Trial Version) formulated by the National Health Commission.

Artemisiae annuae Herba) (added later) 10g, Cang Zhu (Atractylodis Rhizoma) 10g, Da Qjng Ye (Isatidis Folium) 10g, Sheng Gan Cao (Glycyrrhizae Radix) 5g. Suggested use: One dose daily, boiled with 400ml water, taking half of the dose in the morning and the other half in the evening. 4.2.3 Moderate cases 4.2.3.1 Dampness and stagnation lung syndrome Clinical manifestations: fever, cough and scanty sputum, or yellow sputum, suffocation, shortness of breath, bloating, and constipation. The tongue is dark red and fat; the coating is greasy or yellow and the pulse is slippery or stringy. Recommended prescription: Sheng Ma Huang (Ephedrae Herba) 6g, Ku Xing Ren (Armeniacae Semen) 15g, Sheng Shi Gao (Gypsum fibrosum) 30g, Sheng Yi Yi Ren (Coicis Semen) 30g, Mao Cang Zhu (Atractylodis Rhizoma) 10g, Guang Huo Xiang (Pogostemonis Herba) 15g, Qing Hao Cao (Artemisiae annuae Herba) 12g, Hu Zhang (Polygoni cuspidati Rhizoma) 20g, Ma Bian Cao (Verbenae Herba) 30g, Gan Lu Gen (Phragmitis Rhizoma) 30g, Ting Li Zi (Lepidii/Descurainiae Semen) 15g, Hua Ju Hong (Citri grandis Exocarpium rubrum) 15g, Sheng Gan Cao (Glycyrrhizae Radix) 10g. Suggested use: One dose daily, boiled with 400ml water, taking half of the dose in the morning and the other half in the evening. 4.2.3.2 Cold dampness lung syndrome Clinical manifestations: low fever, submerged fever or absence of fever, dry cough, scanty sputum, fatigue, chest tightness, stuffy and full sensation in the stomach, or nausea. The tongue is pale or red, and the coating is white or greasy, and the pulse is soggy. Recommended prescription: Cang Zhu (Atractylodis Rhizoma) 15g, Chen Pi (Citri reticulatae Pericarpium) 10g, Hou Po (Magnoliae officinalis Cortex) 10g, Huo Xiang (Pogostemonis Herba) 10g, Cao Guo (Tsaoko Fructus) 6g, Sheng Ma Huang (Ephedrae Herba) 6g, Qiang Huo (Notopterygii Rhizoma seu Radix) 10g, Sheng Jiang (Zingiberis Rhizoma recens) 10g, Bing Lang (Arecae Semen) 10g. Suggested use: one dose daily, boiled with 400ml water, taking half of the dose in the morning and the other half in the evening

Discharge Criteria and After-discharge Considerations 1. Discharge criteria (1) Body temperature is back to normal for more than three days

Respiratory symptoms improve obviously